Angiotech announces further European expansion of the Quill(TM) SRS PDO product line



    VANCOUVER, Sept. 20 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:  
ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company,
today announced that it has received CE Mark approval to begin marketing
additional diameters of its Quill(TM) Self-Retaining System (SRS)
Polydioxanone (PDO) product line in Europe.
    The Quill(TM) SRS PDO is a longer-lasting absorbable suture, which is
typically used for deeper tissue closures. With CE Mark approval to market the
additional 3-0 and 4-0 sizes of Quill(TM) SRS PDO, Angiotech now offers
diameters ranging from sizes 2 to 4-0 in Europe.
    "The availability of these additional PDO sizes in Europe will allow our
sales force to offer an even broader range of Quill(TM) SRS products, ensuring
we have multiple solutions for a variety of wound closure and tissue
approximation procedures," said Dr. Santi Corsaro, Vice President, Sales &
Marketing (OUS) for Angiotech.
    Angiotech plans to exhibit the Quill(TM) SRS product line at the upcoming
Annual Meeting of the American Society of Plastic Surgeons (ASPS) to be held
on October 26-31, 2007 in Baltimore, MD.

    About the Quill(TM) Self-Retaining System (SRS)

    The innovative Quill(TM) SRS represents the next generation of wound
closure technology. A patented helical barbed design enables surgeons to
suture without the use of knots. The absence of knots provides a wide range of
clinical and economic benefits, including:

    
    Potential to improve patient outcomes:
    -   Minimizes complications associated with knots
    -   Potential to improve wound healing
    -   May enhance cosmesis

    Potential to save time in the operating room:
    -   Achieves potentially significant time savings, especially in suture
        intensive procedures

    Enhanced procedural techniques:
    -   Allows closure of difficult wounds
    -   Enables suturing in tight places
    -   Allows the surgeon to control tension
    

    Note on Forward Looking Statements

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements in this release include but are not limited to
statements regarding: financial benefits to Angiotech that could potentially
be realized from Angiotech's wound closure business, the ability of Angiotech
to commercialize the Quill(TM) SRS product and to develop and commercialize
any successive product lines, that a substantial market exists for the
product, that the product will perform as expected, that the product
represents an improvement over current wound closure methods and that these
improvements could be beneficial to physicians and to patients. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results, events or developments to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements. Many such risks, uncertainties
and other factors are taken into account as part of our assumptions underlying
these forward-looking statements and include, among others, the following;
general economic and business conditions, both nationally and in the regions
in which we operate; market demand; technological changes that could impact
our existing products or our ability to develop and commercialize future
products; competition; existing governmental regulations and changes in, or
the failure to comply with, governmental regulations; decisions, and the
timing of decisions, made by health regulatory agencies regarding approval of
our technology and products; the requirement for substantial funding to
conduct research and development and to expand commercialization activities;
and any other factors that may affect performance. In addition, our business
is subject to certain operating risks that may cause the actual results
expressed or implied by the forward-looking statements in this report to
differ materially from our actual results. These operating risks include; poor
performance of the product in the clinical setting; adverse events related to
the use of the product; improper estimation of the size of the wound closure
market; adverse results or unexpected delays in clinical development
processes; our ability to attract and retain qualified personnel; our ability
to successfully complete preclinical and clinical development of our products;
changes in business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection resulting from
third party challenges to our patents; commercialization limitations imposed
by patents owned or controlled by third parties; our ability to obtain rights
to technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; our ability to continue to integrate into
our business the operations of American Medical Instruments Holdings, Inc. and
our ability to achieve the operational and other synergies and the other
commercial or financial benefits expected as a result of that acquisition; and
any other factors referenced in our annual information form and other filings
with the applicable Canadian securities regulatory authorities or the SEC.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.

    Quill(TM) is a trademark of Quill Medical, Inc, a wholly-owned
    subsidiary of Angiotech Pharmaceuticals, Inc.
    (C)2007 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.





For further information:

For further information: Jodi Regts, Senior Manager, Investor Relations
and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,
jregts@angio.com; Analysts and Investors: Deirdre Neary, Manager, Investor
Relations, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890